Angiosuppressive treatment of malignant glioma - analysis of molecular mechanisms for clinical implication -

恶性胶质瘤的血管抑制治疗-临床意义的分子机制分析-

• 批准号: 10671282
• 负责人: TAKANO Shingo
• 金额: $ 2.11万
• 依托单位: University of Tsukuba
• 依托单位国家: 日本
• 项目类别: Grant-in-Aid for Scientific Research (C)
• 财政年份: 1998
• 资助国家: 日本
• 起止时间: 1998 至 1999
• 项目状态: 已结题
• 来源: https://kaken.nii.ac.jp/grant/KAKENHI-PROJECT-10671282/
• 关键词: angiogenesis; glioma; VEGF; Theobromin; pentoxifyllin; cranial window model; thrombospondin; interferon-β; promoter; thrombospondin 1; thymidine phosphorylase; IP10; interferon-β

1) Angiogenic balance in gliomas : Expression of various angiogenic factor and inhibitors was investigated in a series of glioma tissues and glioma cells. The expression balance of VEGF / thrombospondin-1 controlled glioma angiogenesis. Interferon β resulted in inhibition of VEGF expression as well as angiogenic inhibitor, IP102) Overexpression of thrombospondin in glioma cells : Thronbospondin-1 expressed plasmid DNA has been used for the transfection (ripofectin method & electroporation). The experiment has been repeated in order to acquire the stable transfectant.3) Mouse & human VEGF / reporter plasmid was constructed. Using luciferase assay, the materials that inhibit VEGF promoter activity was investigated. Thrombospondin, genistein, mithramycin, and theobromin inhibited the VEGF promoter activity, resulting in inhibition of VEGF mRNA and protein expression of glioma cells and glioma induced endothelial cell migration. Pentoxyfillin also inhibited VEGF mRNA and protein expression of glioma cells, resulting in inhibition of glioma induced endothelial cell migration.4) Using mouse cranial window model implanted U87 tumor fragment, above-mentioned inhibitors of VEGF activity have been investigated for their intravital anti-angiogenic activity.

1）神经胶质瘤的血管生成：在一系列的胶质瘤和胶质瘤中，VEGF / THELOSPOSHIN-1的表达平衡。抑制剂，IP102）在神经胶质瘤细胞中的血小板蛋白过表达：Thronbospondin-1表达的质粒DNA已贝素（Ripofectin方法与电体）已进行了beensens the Beatement。构建。植物酶测定法，Mithramycin和Theobromin抑制VEGF启动子活性，从而抑制VEGF mRNA和蛋白质的蛋白质细胞和细胞的蛋白质表达。肿瘤碎片ED用于静脉内抗发酵活性。

项目成果

Takano S, Tsukada A, Kujiraoka Y, Sato H, Tomono Y, Nose T.: "Space occupying mass lesion 2 months after radiation therapy for glioma - case report-"Brain Tumor Pathol (Japanese). 16 supple. 115 (1999)

Takano S、Tsukada A、Kujiraoka Y、Sato H、Tomono Y、Nose T.：“神经胶质瘤放射治疗后 2 个月出现占位性肿块病变​​ - 病例报告 -”脑肿瘤病理（日语）。

Takano S.,Tsuboi K.,Matsumura A.,Tomono Y.,Mitsui Y.,Nose T.: "Expression of the angiogenic factor thymidine phosphorylase in human astrocytic tumors"J.Cancer Res.Clin.Oncol.. 126. 145-152 (2000)

Takano S.、Tsuboi K.、Matsumura A.、Tomono Y.、Mitsui Y.、Nose T.：“人星形细胞肿瘤中血管生成因子胸苷磷酸化酶的表达”J.Cancer Res.Clin.Oncol.. 126. 145

高野晋吾、坪井康次、趙大文、松村明、伴野悠士、能勢忠男: "髄膜腫と神経膠芽腫における血管新生の分子病理学的差異"Brain Tumor Pathol(supple). 16. 47 (1999)

Shingo Takano、Koji Tsuboi、Da-wen Cho、Akira Matsumura、Yuji Banno、Tadao Nose：“脑膜瘤和胶质母细胞瘤血管生成的分子病理学差异”脑肿瘤病理（补充）16. 47（1999）。

高野晋吾、坪井康次、趙 大文、松村 明、伴野悠士、能勢忠男: "髄膜腫と神経膠芽腫における血管新生の分子病理学的差異"Brain Tumor Pathol (supple). 16. 47 (1999)

Shingo Takano、Koji Tsuboi、Dawen Cho、Akira Matsumura、Yuji Banno、Tadao Nose：“脑膜瘤和胶质母细胞瘤血管生成的分子病理学差异”《脑肿瘤病理》（补充）16. 47 (1999)。

Takano S, Tsuboi K, Matsumura A, Tomono Y, Mitsui Y, Nose T.: "Expression of the angiogenic factor thymidine phosphorylase in human astrocytic tumors."J Cancer Res Clin Oncol. 126. 145-152 (2000)

Takano S、Tsuboi K、Matsumura A、Tomono Y、Mitsui Y、Nose T.：“血管生成因子胸苷磷酸化酶在人星形细胞肿瘤中的表达。”J Cancer Res Clin Oncol。